Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acro Biomedical CoACBM EV-to-EBIT is -12.80 as of Aug. 02, 2026. The stock has 2 warning signs investors should review. Among 151 Diversified Financial Services companies, Acro Biomedical Co ranks worse than 662250.99% on this metric.
Acro Biomedical Co (OTCPK:ACBM) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Acro Biomedical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $1.56 Mil.
Acro Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acro Biomedical Co EV-to-EBIT Related Terms
Acro Biomedical Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Acro Biomedical Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Shell Companies subindustry, Acro Biomedical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acro Biomedical Co EV-to-EBIT vs Diversified Financial Services Industry
For the Diversified Financial Services industry and Financial Services sector, Acro Biomedical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Acro Biomedical Co's EV-to-EBIT falls into.
Acro Biomedical Co's current Enterprise Value is $1.58 Mil.
Acro Biomedical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acro Biomedical Co (ACBM) has a EV-to-EBIT of -12.80 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acro Biomedical Co and its competitors. According to the industry distribution chart, Acro Biomedical Co ranks #999999 out of 151 companies in the Diversified Financial Services industry.
Is Acro Biomedical Co's EV-to-EBIT too high?
Acro Biomedical Co's current EV-to-EBIT is -12.80. Based on the distribution chart, Acro Biomedical Co ranks #999999 out of 151 companies in the Diversified Financial Services industry, which is in the bottom quartile relative to peers.
How does Acro Biomedical Co's EV-to-EBIT compare to RNGC and EEGI?
According to the Diversified Financial Services industry distribution chart, Acro Biomedical Co ranks #999999 out of 151 companies for EV-to-EBIT. This places Acro Biomedical Co in the lower half of its industry. The industry median EV-to-EBIT is 4.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Diversified Financial Services company?
The median EV-to-EBIT among Diversified Financial Services companies is 4.56, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Acro Biomedical Co and its competitors. For the Diversified Financial Services industry, the median EV-to-EBIT is 4.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acro Biomedical Co's current EV-to-EBIT is -12.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acro Biomedical Co stock overvalued right now?
Acro Biomedical Co (ACBM) has a current EV-to-EBIT of -12.80. The current EV-to-EBIT is -12.80. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Acro Biomedical Co (ACBM), the current EV-to-EBIT is -12.80 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACBM has been successfully added to your 
